Physician profile
Aaron Daniel Tyner
NPI 1902319239
$2,445.06
in general payments reported to CMS, 2019-2025
23 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $616 · 2024: $542 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,445.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $366.23 | 2023-2025 | Evoque |
| Boston Scientific Corporation | $341.74 | 2023-2025 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $272.54 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $259.68 | 2025 | Amvuttra |
| Medtronic, INC. | $175.97 | 2023 | Hawkone |
| Abbott Laboratories | $161.78 | 2023-2025 | Xience Skypoint, Ensite |
| Amgen INC. | $156.46 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $116.05 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $102.77 | 2023-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $78.07 | 2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $69.71 | 2023-2025 | |
| Bridgebio Pharma, INC. | $67.08 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $41.45 | 2023 | |
| Impulse Dynamics (USA) INC. | $34.90 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $33.32 | 2024 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $26.97 | 2024 | (5091) Amb Mon & Diag Und |
| Novo Nordisk INC | $25.55 | 2025 | Wegovy |
| Baxter Healthcare | $23.45 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $23.40 | 2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.39 | 2023 | Jardiance |
| Heartflow, INC. | $17.80 | 2025 | |
| Atricure, INC. | $14.83 | 2024 | |
| Scpharmaceuticals INC. | $13.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Tyner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.